-
Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19 J. Hepatol. (IF 26.8) Pub Date : 2024-06-20 Massimiliano Cadamuro, Alberto Lasagni, Claudia Maria Radu, Arianna Calistri, Matteo Pilan, Clarissa Valle, Pietro Andrea Bonaffini, Adriana Vitiello, Serena Toffanin, Camilla Venturin, Yahima Friòn-Herrera, Sandro Sironi, Maria Grazia Alessio, Giulia Previtali, Michela Seghezzi, Andrea Gianatti, Mario Strazzabosco, Alastair J. Strain, Elena Campello, Luca Spiezia, Giorgio Palù, Anna Chiara Frigo,
Mechanisms and clinical impact of portal microthrombosis featuring severe COVID-19 are unknown. Intrapulmonary vascular dilation (IPVD)-related hypoxia has been described in severe liver diseases. We hypothesized that portal microthrombosis is associated with IPVD and fatal respiratory failure in COVID-19. Ninety-three patients who died from COVID-19, were analysed for portal microvascular damage (histology)
-
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide J. Hepatol. (IF 26.8) Pub Date : 2024-06-18 Pierluigi Toniutto, Edmondo Falleti, Sara Cmet, Annarosa Cussigh, Elisabetta Degasperi, Maria Paola Anolli, Dana Sambarino, Floriana Facchetti, Marta Borghi, Riccardo Perbellini, Sara Monico, Pietro Lampertico
-
Reply to: “Mycophenolate mofetil in autoimmune hepatitis: Are we ready for primetime?” J. Hepatol. (IF 26.8) Pub Date : 2024-06-15 Charlotte D. Slooter, Anna E.C. Stoelinga, Romée J.A.L.M. Snijders
-
Integration of new technologies in the multidisciplinary approach to primary liver tumours: The next-generation tumour board J. Hepatol. (IF 26.8) Pub Date : 2024-06-11 Jean-Charles Nault, Julien Calderaro, Maxime Ronot
Primary liver tumours, including benign liver tumours, hepatocellular carcinoma and cholangiocarcinoma, present a multifaceted challenge, necessitating a collaborative approach, as evidenced by the role of the multidisciplinary tumour board (MDTB). The approach to managing primary liver tumours involves specialised teams, including surgeons, radiologists, oncologists, pathologists, hepatologists, and
-
Reply to: “Evidence and choice: The BCLC vision for tailoring clinical decision-making” J. Hepatol. (IF 26.8) Pub Date : 2024-06-11 Franco Trevisani, Alessandro Vitale, Agostino Colli, Masatoshi Kudo, Laura Kulik, Joon-Won Park, David J. Pinato, Umberto Cillo
-
Reply to: ‘Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe’ J. Hepatol. (IF 26.8) Pub Date : 2024-06-11 Lesley A. Patmore, Milan J. Sonneveld
-
Reply to: “Non-acute decompensation cannot be ignored in future research and clinical practice” J. Hepatol. (IF 26.8) Pub Date : 2024-06-10 Marta Tonon, Anna Barone, Valeria Calvino, Valeria Santori, Paolo Angeli
-
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Eric J. Lawitz, Mandy Fraessdorf, Guy W. Neff, Jörn M. Schattenberg, Mazen Noureddin, Naim Alkhouri, Bernhard Schmid, Charles P. Andrews, István Takács, Samina Ajaz Hussain, Wiebke K. Fenske, Edward J. Gane, Azadeh Hosseini-Tabatabaei, Arun J. Sanyal, Daniel F. Mazo, Ramy Younes, for the NCT05296733 Investigators
-
THU-375 When glecaprevir/pibrentasvir ultra-short therapy is enough to eradicate HCV infection J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Alberto Grassi, Natascia Celli, Silvana Maccariello, Gabriele Donati, Angela Fabbri, Giorgio Ballardini
-
THU-374 Description of age, sex, and characteristics of hepatitis C patients in the SVR10 K study: a real-world SOF/VEL analysis performed across five global regions J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Soo Aleman, Fatima Higuera-de-la-Tijera, Francisco Javier Garcia-Samaniego, Marta Casado-Martin, Grace Lai-Hung Wong, Mohammed Alzaabi, Habiba Kamal, Karin Lindahl, Aastha Chandak, Marta Martinez, Artak Khachatryan, Linda Chen, Candido Hernández, Kim Vanstraelen, Ming-Lung Yu
-
THU-373-YI Quality of etiotropic therapy efficasy of chronic hepatitis C patients in accordance of toll-like receceptor 4 +3725G/C gene polymorfisms variety J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Tetiana Bevz, Larysa Moroz, Kiarina Myroniuk-Konstantynovych, Iryna Bondaruk, Galyna Martyniuk, Yaroslav Demchyshyn
-
THU-372-YI Point of care hepatitis C screening and treatment among people who use drugs in new york city addiction centers: barriers and opportunities J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Jessica Siguencia, Jhané Phanor, Anthony Choi, Robert S. Brown Jr, Laura Maroldo
-
THU-371 Impact of a simplified diagnosis-monitoring strategy on Glecaprevir/Pibrentasvir (G/P) treatment initiation and response in patients with chronic hepatitis C virus (HCV) infection receiving opioid substitute therapy in Israel-a real world evidence J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Eli Zuckerman, Orly Azulay
-
THU-370 Hepatocellular carcinoma may be a viral reservoir during treatment of hepatitis C with direct-acting antivirals J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Mário Jorge Silva, Ana Patricia Negrinho, Fatima Oliveira Martins, Antonio Figueiredo, Helena Gloria, Carina Santos, Pedro Lages Martins, Vasco Ribeiro, Mario Oliveira, Hugo Pinto Marques, Silvia Vilares Conde, Filipe Calinas
-
THU-367-YI Effectiveness and safety of direct-acting antivirals in the treatment of elderly people infected with HCV J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Michał Brzdęk, Dorota Zarębska-Michaluk, Krzysztof Tomasiewicz, Magdalena Tudrujek-Zdunek, Beata Lorenc, Włodzimierz Mazur, Hanna Berak, Justyna Janocha-Litwin, Jakub Klapaczynski, Ewa Janczewska, Dorota Dybowska, Anna Parfieniuk-Kowerda, Piekarska Anna, Jerzy Jaroszewicz, Robert Flisiak
-
THU-366 Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: Data from the German Hepatitis C-Registry (2016–2022) J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Markus Cornberg, Gerlinde Teuber, Ralf Link, Uwe Naumann, Hartwig Klinker, Christine John, Candido Hernández, Marianna Schwenken, Christoph Sarrazin
-
THU-365 Real-world effectiveness and safety of 8-week glecaprevir/ pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Chung-Feng Huang, Te-Sheng Chang, Hsing-Tao Kuo, Chien-Wei Huang, Lien-Ray Mo, Chi-Ming Tai, Kuo-Chih Tseng, Ming-Jong Bair, Sih-Ren Wang, Ching-Chu Lo, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Chih-Lang Lin, Chi-Chieh Yang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Sheng-Shun Yang, Chia-Chi Wang, Jui-Ting Hu
-
THU-364 Modeling suggests that undetectable HCV at week 2 of DAA therapy could identify patients for shorter treatment duration J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Ashish Goyal, Ohad Etzion, Kimberly Page, Tatyana Kushner, Yedidya Saiman, Scott Cotler, Harel Dahari
-
THU-363 Validation of a modified pediatric formulation of Sofosbuvir and Daclatasvir in genotype-4 HCV-infected children weighing 17– 35 Kg J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Ahmed Farrag, Maggie Abbassi, Fatma Ebeid, Tim Cressey, Philippa Easterbrook, Nirmeen Sabry, Manal El-Sayed
-
THU-362 Ravidasvir in combination with sofosbuvir for 12 or 24 weeks achieved high sustained virological response rates in genotype 3 chronic hepatitis C without or with compensated liver cirrhosis J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Soek Siam Tan, Caroline Menétrey, Isabela Ribeiro, Nicolas Salvadori, Sabine Yerly, Nicole Ngo-Giang-Huong, Graciela Diap
-
THU-420 Evaluation of LiverRisk score as predictor of liver fibrosis and mortality in patients with HCV-related hepatitis treated with direct acting antivirals J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Antonietta Romano, Amalia Rita Caspanello, Salvatore Piano, Marta Tonon, Carmine Gambino, Valeria Calvino, Anna Barone, Nicola Zeni, Simone Incicco, Roberta Gagliardi, Paolo Angeli
-
THU-419 Regression of hepatic fibrosis in patients with chronic hepatitis C treated with direct-acting antivirals (DAAs). A long-term, prospective, observational study J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Evdoxia Avramopoulou, Efthymios Tsounis, Stavros Kanaloupitis, Konstanitnos Zisimopoulos, Maria Kalafateli, Ioanna Aggeletopoulou, Christos Sotiropoulos, Theodora Kafentzi, Georgios Geramoutsos, Odysseas Ampazis, Georgia Diamantopoulou, Angeliki Tsintoni, Konstantinos Thomopoulos, Christos Triantos
-
THU-418 Screening for chronic hepatitis C in pre-surgical patients J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Mercedes Vergara, Gemma Solé, Isabel Esteve, Meritxell Casas, Jordi Sánchez, Cristina Solé, José Alberto Ferrusquía, Mireia Miquel
-
THU-414 Incidence of hepatocellular carcinoma in patients with hepatitis C treated with direct-acting antivirals agents: results of a long-term prospective study period J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Emanuela De Santis, Alessandro Caioli, Fernando De Angelis, Adriano De Santis
-
THU-413 Baseline gamma-glutamyl transpeptidase levels are associated with aggravation of esophagogastric varix after direct-acting antiviral therapy in cirrhotic patients with hepatitis C virus J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Yuki Tahata, Hayato Hikita, Satoshi Mochida, Akio Ido, Daiki Miki, Ryotaro Sakamori, Hitoshi Yoshiji, Norifumi Kawada, Nobuyuki Enomoto, Taro Yamashita, Masayuki Kurosaki, Hidekatsu Kuroda, Yoichi Hiasa, Kazuhiko Nakao, Naoya Kato, Goki Suda, Yasunari Nakamoto, Hiroshi Yatsuhashi, Kentaro Matsuura, Taro Takami, Eiji Kakazu, Yoshito Itoh, Yasuhiro Asahina, Yoshiyuki Ueno, Ryosuke Tateishi, Shuji Terai
-
THU-412 Hepatitis C lost to follow-up rates in primary care practices in Belgium J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Marie Coessens, Jeoffrey Schouten, Wim Verlinden
-
THU-411 Long term liver-related events in patients with HCV-related liver disease and advanced fibrosis after sustained virological response with direct-acting antivirals J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Jorge Barajas, Tomás Artaza, JuanJosé Sánchez-Ruano, Marta Romero-Gutiérrez, Carolina Delgado, Gema De la Cruz, Concepción Gonzalez, Raquel Lomas, Rafael Gómez Rodríguez
-
THU-410 Clinical interventions and use of resources for the management of adverse effects associated with multiple drug interactions in the hepatitis C population J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Juan Turnes, Antonio Garcia Herola, Ramón Morillo Verdugo, Marinela Mendez, Candido Hernández, Antoni Sicras Mainar
-
THU-408 The prognostic influence of toll-like receptor 4 +3725G/C gene polymorphism on biochemical profile among chronic HCV hepatitis patients J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Tetiana Bevz, Iryna Bondaruk, Kiarina Myroniuk-Konstantynovych, Larysa Moroz, Galyna Martyniuk, Yaroslav Demchyshyn
-
THU-407 A new pattern for hepatitis C management in hospital: establishment and effectiveness verification J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Dong Yan, Siheng Zhu, Xiaoting Ye, Heqing Huang
-
THU-406 Knowledge, perceptions and barriers to the diagnosis and treatment of hepatitis C among persons who inject drugs: findings from the Educate-Test-Treat (ETT) programme in Singapore J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Alyssa Sim, Shann Long, Sanchalika Acharyya, Gerard Wong, Ryan Jia Jie Liew, Kuo Chao Yew
-
THU-405 Analysis of a decentralized model interdisciplinary for the elimination of HCV in vulnerable population in the province of Huelva (Spain). To continue advancing in the elimination of hepatitis C, it is necessary to establish a clearly defined integrated care plan J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Gema Romero, Ana Bejarano, Francisco Franco, Pilar Del Pino, Maria Dolores Santos
-
THU-404 Impact of hepatitis C treatment on mortality among liver cancer patients in Georgia-2015–2022 J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Anna Khoperia, Maia Butsashvili, Shaun Shadaker, Susan Gawel, Sophia Surguladze, Nazibrola Chitadze, Konstantine Kazanjan, Vladimer Getia, Lasha Gulbiani, Geoff Beckett, Alan Landay, Maia Tsereteli, Maia Alkhazashvili, Amiran Gamkrelidze, Francisco Averhoff
-
THU-403 Liver fibrosis and steatosis in children after effective treatment of chronic hepatitis C using direct acting antivirals J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Maria Pokorska-Śpiewak, Ewa Talarek, Anna Dobrzeniecka, Małgorzata Aniszewska, Magdalena Pluta, Magdalena Marczyńska
-
THU-402 Higher cardiovascular burden in people living with HIV (PLWH) with metabolic syndrome and history of HCV infection J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Alessia Siribelli, Michele Bellomo, Camilla Muccini, Riccardo Lolatto, Giulia Morsica, Sara Diotallevi, Nicola Gianotti, Simona Bossolasco, Costanza Bertoni, Vincenzo Spagnuolo, Antonella Castagna, Hamid Hasson
-
THU-399-YI Burden of extrahepatic manifestations after HCV cure: assessing the effect of IFN versus DAA-induced SVR in a large population-based cohort in British Columbia, Canada J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Dahn Jeong, Stanley Wong, Jean Damascene Makuza, Héctor Alexander Velásquez García, Mel Krajden, Richard Morrow, Prince Adu, Sofia Bartlett, Georgine Cua, Amanda Yu, Maria Alvarez, Naveed Janjua
-
THU-398 Metabolic factors predict significant liver fibrosis in people who use drugs (PWUD) and general population with HCV infection. Time to re-consider the follow-up strategy in chronic hepatitis C patients J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Hariklia Kranidioti, Olga Anagnostou, Georgios Kontos, Sofia Vasileiadi, Anestis Goulas, Nikolaos Papadopoulos, Melanie Deutsch, Spilios Manolakopoulos
-
THU-397-YI Long-term histological fibrosis evolution following sustained virological response after hepatitis C-recurrence in livertransplanted patients J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Tibo Lemmens, Cindy Serdjebi, Guillaume Henin, Selda Aydin, Pamela Baldin, Florine Chandes, Géraldine Dahlqvist
-
THU-396 HCV patients achieving sustained virologic response after direct-acting antiviral therapy may still face adverse clinical outcomes: analysis of gene enrichment, marker expression, and clinical outcomes J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Daniel Millian, Omar Saldarriaga, Esteban Arroyave, Heather Stevenson, Arvind Rao, Santhoshi Krishnan
-
THU-395 Is hepatitis C screening based on risk factors enough in primary care setting? J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Elena Vargas-Accarino, Ariadna Rando-Segura, Ingrid Arcusa, Eva de Diego, Núria García, Elena Monserrat, Marta Selvi, Maria Asuncion Ubeda Pastor, Imma Valls, Carla Ventosa, Adriana Palom, Judit Romero-Vico, Juan Carlos Ruiz-Cobo, Mar Riveiro Barciela, Rafael Esteban, Maria Buti
-
THU-394 Improvement of hepatitis C virus care cascade by In-hospital Reflex tEsting ALarm-C (REAL-C) model J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Jonggi Choi, Kanghee Park, Jina Park, Ji won Yang, Hyeyeon Hong, Sung Won Chung
-
THU-391-YI Impact of hepatitis C cure on outcomes for patients undergoing curative therapy for hepatocellular carcinoma J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Alex Wynne, Edward J. Gane, Akhilesh Swaminathan
-
THU-390 Achieving HCV elimination in underserved populations-an austrian initiative for HCV care for homeless people without medical insurance J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Caroline Schwarz, Bernadette Becsi, Stephan Leick, Stephan Gremmel, Lena Wien, Enisa Gutic, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler
-
THU-389 Sustained virological response after early discontinuation of HCV treatment J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Robert Flisiak, Dorota Zarębska-Michaluk, Ewa Janczewska, Anna Parfieniuk-Kowerda, Włodzimierz Mazur, Marek Sitko, Justyna Janocha-Litwin, Rafal Krygier, Beata Lorenc, Anna Piekarska, Barbara Sobala-Szczygieł, Krystyna Dobrowolska, Łukasz Socha, Jerzy Jaroszewicz
-
THU-387 Safety and efficacy of two pangenotypic direct acting antivirals (sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) for the treatment of hepatitis C in children J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Maria Pokorska-Śpiewak, Ewa Talarek, Anna Dobrzeniecka, Małgorzata Aniszewska, Magdalena Pluta, Magdalena Marczyńska
-
THU-386-YI Renin-angiotensin inhibitor intake is associated with improved survival in patients with chronic hepatitis C viral infection following SVR-data from the german hepatitis C-registry (DHC-R) J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Tammo Lambert Tergast, Marie Griemsmann, Leyla Valiyeva, Peter Buggisch, Stefan Mauss, Hartwig Klinker, Klaus H.W. Boeker, Christine John, Ralf Link, Stefan Zeuzem, Thomas Berg, Heiner Wedemeyer
-
THU-383 Predictive performance of HCC risk scores in chronic hepatitis C patients with advanced fibrosis after achieving SVR: real-world experience from a tertiary UK centre J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Riham Soliman, Saima Ajaz, James Lok, Mercy Karoney, Evangelos Chalatsis, Ivana Carey, Mary D Cannon, Kathryn Oakes, Teresa Bowyer, Kosh Agarwal, Maria Guerra Veloz
-
THU-382 Lead-in cohort results from a phase 2 study of a novel 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Alina Jucov, Brian Conway, Laura Iliescu, Paul Mitrut, Simin Florescu, Roxana Cernat, Elena Ermacicova, Shannan Lynch, Marina Majarian, Sergey Izmailyan, Xiao-Jian Zhou, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond
-
THU-381 Prognostic implications of liver stiffness impairment after HCV cure in cACLD patients J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Monica Pons, Georg Semmler, Sonia Alonso Lopez, Sabela Lens, Elton Dajti, Marie Griemsmann, Alberto Zanetto, Lukas Burghart, Stephanie Hametner-Schreil, Lukas Hartl, Maria Luisa Manzano Alonso, Sergio Rodriguez-Tajes, Paola Zanaga, Michael Schwarz, Maria Luisa Gutierrez, Mathias Jachs, Anna Pocurull, Benjamin Polo Lorduy, Dominik Ecker, Beatriz Mateos Muñoz, Sonia Izquierdo, Yolanda Real Martínez,
-
THU-380-YI Individualized intervals for streamlined directly observed therapy in PWIDs-a unique approach to continue HCV microelimination throughout the COVID19 pandemic J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Caroline Schwarz, Angelika Schütz, David Bauer, Enisa Gutic, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler
-
THU-379 Artificial intelligence model for predicting liver-related events in non-cirrhotic patients after successful treatment by direct-acting antivirals for chronic hepatitis C J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Huapeng Lin, Jimmy Che-To Lai, Hye Won Lee, Terry Cheuk-Fung Yip, Sang Hoon Ahn, Grace Lai-Hung Wong, Xiangjun Meng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim
-
THU-378 Prediction of outcomes in patients with HCV compensated liver cirrhosis after SVR: results from 5-years of follow-up J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Filomena Morisco, Alessandro Federico, Massimo Marignani, Flavia L Lombardo, Valentina Cossiga, Luisa Ranieri, Mario Romeo, Marina Cipullo, Paola Begini, Federico Gioli, Tommaso Stroffolini
-
TOP-385-YI Evaluation of liver fibrosis in patients with advanced chronic liver disease due to hcv after 6 years of sustained viral response. study with paired biopsies at 3 and 6 years J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Lidia Canillas, Dolores Naranjo, Teresa Broquetas, Zoe Mariño, Xavier Forns, Jose A. Carrión
-
WED-389 Pharmacokinetics and safety of the monoclonal antibody tobevibart (VIR-3434) administered as monotherapy or in combination with the small interfering RNA elebsiran (VIR-2218) in cirrhotic participants with mild hepatic impairment J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Li Wang, Sneha Gupta, Michael A. Chattergoon, Asma El-zailik, Cheng Huang, George Hristopoulos, Maribel Reyes
-
WED-388 Safety, tolerability, and hepatitis B surface antigen reduction of HT-101 in chronic hepatitis B patients: preliminary results from a phase I b study J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Dong Wang, Shanzhong Zhang, Yanqin Ma, Lijuan Ding, Zhipeng Zhang, Hong Ma, Jidong Jia
-
WED-387 Study on the role of dendritic cells in CHB patients treated with intermittent Interferon therapy J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Liu Yang, Tingting Jiang, Shiyu Wang, Ziyu Zhang, Xinxin Li, Yao Xie, Minghui Li
-
WED-386 A double-blind, placebo-controlled, single-ascending dose phase I a study to evaluate the safety, tolerability, and pharmacokinetics of HT-101, an investigational small interfering ribonucleic acid targeting hepatitis B virus in Chinese healthy subjects J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Jianxiong Zhang, Dong Wang, Shanzhong Zhang, Yanqin Ma, Lijuan Ding, Zhipeng Zhang, Hong Ma, Jidong Jia, Ruihua Dong
-
WED-383 Antiviral efficacy of REP 2139-Mg and effects on HVPG in HDV/HBV coinfected patients with cirrhosis and portal hypertension nonresponding to previous bulevirtide treatment J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Mathias Jachs, Michael Schwarz, Michel Bazinet, Mattias Mandorfer, Thomas Reiberger, Andrew Vaillant
-
WED-382 Modeling dual antiviral activity of lonafarnib to explain hepatitis D virus RNA negativity 24 weeks after end of therapy despite RNA positivity at end of therapy: The D-LIVR study J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Adquate Mhlanga, Harel Dahari, Leeor Hershkovich, Scott Cotler, Ingrid Choong, Colin Hislop, Theo Heller, Christopher Koh, Jeffrey Glenn, Tarik Asselah, Saeed Sadiq Hamid, Ohad Etzion
-
WED-381 A double-blind, placebo-controlled, single-ascending dose phase I a study to evaluate the safety, tolerability, and pharmacokinetics of HT-102, a neutralizing antibodies against the hepatitis B surface antigen in Chinese healthy volunteers J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Mingjian Zhang, Dong Wang, Shanzhong Zhang, Yanqin Ma, Lijuan Ding, Zhipeng Zhang, Lungen Lu, Xueying Ding